Efficacy and safety of denosumab in the treatment of prostate cancer with bone metastases:A systematic review and meta-analysis
10.13263/j.cnki.nja.2025.04.011
- VernacularTitle:地诺单抗治疗前列腺癌骨转移安全性和有效性的系统评价与meta分析
- Author:
Li YANG
1
;
Bo FANG
;
Can-qin HE
;
Xu-xin ZHAN
;
You-ping XIAO
;
Xiao-jun QIN
;
Qiang LOU
;
Xue-jun SHANG
Author Information
1. 贵州中医药大学第二附属医院脊柱骨科,贵州贵阳 550001
- Publication Type:Journal Article
- Keywords:
denosumab;
prostate cancer with bone metastasis;
meta-analysis;
systematic review;
randomized controlled trial
- From:
National Journal of Andrology
2025;31(4):349-356
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of denosumab in the treatment of prostate cancer with bone metastases.Methods:Relevant studies were retrieved from PubMed,EMBASE,Cochrane,Web of Science,Sinomed,CNKI and Wanfang data-bases.The Cochrane risk-of-bias assessment tool was used to evaluate the quality of included studies,and relevant data were extracted.meta-analysis was performed using RevMan 5.4 and RStudio software,and forest plots were generated.Results:Six randomized con-trolled trials(RCTs)were included.Compared with the control group,denosumab significantly reduced the risk of skeletal-related e-vents(HR=0.78,95％CI:0.62-0.93).In terms of safety,denosumab did not increase the risk of total adverse events,severe adverse events and the adverse events higher than CTC grade 3.Conclusion:Denosumab can delay the time to first skeletal-related event with good safety.However,due to the limitations of this study,further high-quality,large-sample,multicenter RCTs are needed to confirm these findings.
